# 試驗數據顯示結直腸癌免疫反應改善。

*biotech · news · 2026-04-15 · Benzinga*

## Key points

- PDS01ADC在結直腸癌中達成78%的客觀反應率，對比未使用者為35%。
- 接受治療的患者兩年存活率超過80%，未使用PDS01ADC者為35%。
- 使用PDS01ADC後中位無進展存活期在13.1個月時尚未達到。
- PDS Biotechnology亦報告NCI主導的前列腺癌試驗中PDS01ADC的早期正面結果。

Trial Data Show Improved Immune Response In Colorectal Cancer The published data from the trial indicate that PDS01ADC significantly enhances immune response in colorectal cancer patients who have failed prior treatments. The stock’s rise follows the publication of findings showing a 78% objective response rate with PDS01ADC versus 35% in a parallel trial without PDS01ADC. This promising result comes from a study that included 22 patients, with a two-year survival rate exceeding 80% for those treated with PDS01ADC versus 35%. Progression-Free Survival Remains Unreached The median progression-free survival (PFS) was not reached at the minimum follow-up of 13.1 months; in the parallel trial without PDS01ADC, the PFS was 8.1 months. Additional Data From Prostate Cancer Study Earlier, the company presented encouraging early results from an NCI-led trial investigating PDS01ADC at the AACR special conference on prostate cancer research. PDSB Stock Price Activity: PDS Biotechnology shares were up 25.47% at $1.33 at the time of publication on Wednesday, according to Benzinga Pro data. Photo by Aunt Spray via Shutterstock

**Companies:** PDS Biotechnology

[Read the full story on Benzinga](https://www.benzinga.com/news/health-care/26/04/51839004/why-is-pds-biotechnology-stock-gaining-wednesday)

---

Canonical: https://newsio.io/zh-TW/n/4f09db56-854b-4dc8-8589-30648fa98cec/pdsbpds-biotechnology25-471-33
Summarized by Newsio from Benzinga. https://newsio.io/how-it-works